对于系统性癌症治疗的pH响应药物输送系统的当前原则,挑战和新指标
Roman A Verkhovskii1, Alexey N Ivanov2, Ekaterina V Lengert2,3
1Science Medical Center, Saratov State University, 83 Astrakhanskaya Str., 410012 Saratov, Russia.
响应pH的药物输送系统为癌症治疗提供了希望,但面临着挑战. 本综述分析了策略,局限性和理想载体配置文件,以指导对刺激反应药物载体的未来发展.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 颗粒物药物递送系统对于克服传统化疗药物的局限性至关重要.
- 具有刺激反应的药物载体,特别是由内源性pH触发的药物载体,是一个显著的趋势.
- 挑战包括非目标积累,免疫性,细胞内传递和制造复杂性.
研究的目的:
- 讨论 pH 响应药物递送的基本策略.
- 分析pH敏感载体的局限性,问题和不良临床结果的原因.
- 定义"理想"药物载体的形状,以适应pH的药物输送.
主要方法:
- 对响应pH的药物输送策略的文献综述.
- 分析运营商应用中的挑战和局限性.
- 使用含有金属的材料作为例子,制定理想的药物载体形状.
- 对这些理想形状进行最近研究的评估.
主要成果:
- 响应pH的药物递送在临床转化中面临重大障碍.
- 现有运营商经常表现出目标之外的积累和制造困难.
- 含有金属的材料为开发改进的pH响应载体提供了潜力.
结论:
- 需要清楚地了解挑战,以推进对pH反应的药物输送.
- 定义理想的载体配置文件可以指导技术的发展.
- 未来的研究应该专注于克服当前的限制,以获得成功的临床应用.
更多相关视频
07:59A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
相关概念视频
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Biopharmaceutics and Pharmacokinetics: Overview
Factors Influencing Drug Absorption: Drug Dissolution
Treatment Resistant Cancers
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
